Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation

Ravikiran Panakanti, Akshay Pratap, Ningning Yang, John S. Jackson, Ram I Mahato

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Liver fibrosis is a consequence of chronic liver disorders which lead to the accumulation of extracellular matrix (ECM). Particularly, there is an increased accumulation of collagen in the fibrotic liver. We have therefore used a triplex forming oligonucleotide (TFO) against the type α1(I) collagen and evaluated, whether it can attenuate liver fibrosis induced by common bile duct ligation (CBDL) in rats. There was a significant decrease in hydroxyproline levels and Masson's trichrome staining for collagen in TFO-treated CBDL groups compared to non-treated CBDL group. There was over expression of type α1(I) collagen, α-smooth muscle actin (α-SMA) and TGF-β1 expression in the CBDL group compared to TFO-treated CBDL group. Also, the serum alanine transaminase (ALT) and aspartate transaminase (AST) concentrations were less in the TFO treated group compared to non-treated CBDL group. There was also less neutrophils accumulation in TFO treated CBDL group assayed by myeloperoxidase (MPO) assay. These results suggests that TFO can be used to downregulate type 1 collagen gene expression and can alleviate liver fibrosis induced by common bile duct ligation.

Original languageEnglish (US)
Pages (from-to)1718-1726
Number of pages9
JournalBiochemical Pharmacology
Volume80
Issue number11
DOIs
StatePublished - Dec 1 2010

Fingerprint

Common Bile Duct
Collagen Type I
Bile Ducts
Oligonucleotides
Liver Cirrhosis
Liver
Ducts
Ligation
Collagen
Hydroxyproline
Aspartate Aminotransferases
Alanine Transaminase
Gene expression
Peroxidase
Extracellular Matrix
Smooth Muscle
Muscle
Rats
Actins
Assays

Keywords

  • Common bile duct ligation
  • Liver fibrosis
  • TGF-β1
  • Triplex forming oligonucleotide
  • Type α1(I) collagen
  • α-SMA

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation. / Panakanti, Ravikiran; Pratap, Akshay; Yang, Ningning; Jackson, John S.; Mahato, Ram I.

In: Biochemical Pharmacology, Vol. 80, No. 11, 01.12.2010, p. 1718-1726.

Research output: Contribution to journalArticle

Panakanti, Ravikiran ; Pratap, Akshay ; Yang, Ningning ; Jackson, John S. ; Mahato, Ram I. / Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation. In: Biochemical Pharmacology. 2010 ; Vol. 80, No. 11. pp. 1718-1726.
@article{df5ee2ff13bc417c85a0b09e219788c2,
title = "Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation",
abstract = "Liver fibrosis is a consequence of chronic liver disorders which lead to the accumulation of extracellular matrix (ECM). Particularly, there is an increased accumulation of collagen in the fibrotic liver. We have therefore used a triplex forming oligonucleotide (TFO) against the type α1(I) collagen and evaluated, whether it can attenuate liver fibrosis induced by common bile duct ligation (CBDL) in rats. There was a significant decrease in hydroxyproline levels and Masson's trichrome staining for collagen in TFO-treated CBDL groups compared to non-treated CBDL group. There was over expression of type α1(I) collagen, α-smooth muscle actin (α-SMA) and TGF-β1 expression in the CBDL group compared to TFO-treated CBDL group. Also, the serum alanine transaminase (ALT) and aspartate transaminase (AST) concentrations were less in the TFO treated group compared to non-treated CBDL group. There was also less neutrophils accumulation in TFO treated CBDL group assayed by myeloperoxidase (MPO) assay. These results suggests that TFO can be used to downregulate type 1 collagen gene expression and can alleviate liver fibrosis induced by common bile duct ligation.",
keywords = "Common bile duct ligation, Liver fibrosis, TGF-β1, Triplex forming oligonucleotide, Type α1(I) collagen, α-SMA",
author = "Ravikiran Panakanti and Akshay Pratap and Ningning Yang and Jackson, {John S.} and Mahato, {Ram I}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.bcp.2010.08.020",
language = "English (US)",
volume = "80",
pages = "1718--1726",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation

AU - Panakanti, Ravikiran

AU - Pratap, Akshay

AU - Yang, Ningning

AU - Jackson, John S.

AU - Mahato, Ram I

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Liver fibrosis is a consequence of chronic liver disorders which lead to the accumulation of extracellular matrix (ECM). Particularly, there is an increased accumulation of collagen in the fibrotic liver. We have therefore used a triplex forming oligonucleotide (TFO) against the type α1(I) collagen and evaluated, whether it can attenuate liver fibrosis induced by common bile duct ligation (CBDL) in rats. There was a significant decrease in hydroxyproline levels and Masson's trichrome staining for collagen in TFO-treated CBDL groups compared to non-treated CBDL group. There was over expression of type α1(I) collagen, α-smooth muscle actin (α-SMA) and TGF-β1 expression in the CBDL group compared to TFO-treated CBDL group. Also, the serum alanine transaminase (ALT) and aspartate transaminase (AST) concentrations were less in the TFO treated group compared to non-treated CBDL group. There was also less neutrophils accumulation in TFO treated CBDL group assayed by myeloperoxidase (MPO) assay. These results suggests that TFO can be used to downregulate type 1 collagen gene expression and can alleviate liver fibrosis induced by common bile duct ligation.

AB - Liver fibrosis is a consequence of chronic liver disorders which lead to the accumulation of extracellular matrix (ECM). Particularly, there is an increased accumulation of collagen in the fibrotic liver. We have therefore used a triplex forming oligonucleotide (TFO) against the type α1(I) collagen and evaluated, whether it can attenuate liver fibrosis induced by common bile duct ligation (CBDL) in rats. There was a significant decrease in hydroxyproline levels and Masson's trichrome staining for collagen in TFO-treated CBDL groups compared to non-treated CBDL group. There was over expression of type α1(I) collagen, α-smooth muscle actin (α-SMA) and TGF-β1 expression in the CBDL group compared to TFO-treated CBDL group. Also, the serum alanine transaminase (ALT) and aspartate transaminase (AST) concentrations were less in the TFO treated group compared to non-treated CBDL group. There was also less neutrophils accumulation in TFO treated CBDL group assayed by myeloperoxidase (MPO) assay. These results suggests that TFO can be used to downregulate type 1 collagen gene expression and can alleviate liver fibrosis induced by common bile duct ligation.

KW - Common bile duct ligation

KW - Liver fibrosis

KW - TGF-β1

KW - Triplex forming oligonucleotide

KW - Type α1(I) collagen

KW - α-SMA

UR - http://www.scopus.com/inward/record.url?scp=77957897062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957897062&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2010.08.020

DO - 10.1016/j.bcp.2010.08.020

M3 - Article

VL - 80

SP - 1718

EP - 1726

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -